Finanzen von Zyversa Therapeutics Inc (ZVSA)ZVSAZyversa Therapeutics Inc

Evaluating the bottom line, Zyversa Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -91.39%, provide a clear picture of how effectively ZVSA converts its operational activities into shareholder value.

In the context of the broader market, ZVSA competes directly with industry leaders such as PRFX and ALZN. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, ZVSA's gross margin of N/A stands against PRFX's -4776.47% and ALZN's N/A. Such benchmarking helps identify whether Zyversa Therapeutics Inc is trading at a premium or discount relative to its financial performance.